Linked Life Data

527159

Source:http://linkedlifedata.com/resource/pubmed/id/527159

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1980-4-17
pubmed:abstractText
This study was conducted on 252 childrens afflicted with Schistosomiasis (S. mansoni and S. haematobium) living in endemic area and treated with doses of 15 mg/kg to 60 mg/kg of Oxamniquine. During eight months, parasitologic and serologic (Indirect fluorescent antibody test) controls were continued. A single per os dose of 15 mg/kg appears best and 87% cure rates were obtained with only 12% reinfestation. Antibody studies indicate, at this dosage, an antigenic stimulation that lasts at least 8 months, thus conferring a "vaccinating" action possible to be used with large population groups. Further studies show acceptable tolerance clinically of Oxamniquine and its ineffectiveness against S. haematobium. As mentioned by others, it appears that Oxamniquine has usefulness in treatment of schistosomiasis due to S. mansoni.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0037-9085
pubmed:author
pubmed:issnType
Print
pubmed:volume
72
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
153-64
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
[Efficacy of UK 4271 (oxamniquine, Pfizer) in Schistosoma mansoni bilharziasis in western Africa (parasitological and serological study of 252 children)].
pubmed:publicationType
Journal Article, English Abstract